Advertisement

Annals of Hematology

, Volume 98, Issue 10, pp 2451–2455 | Cite as

Low-dose pembrolizumab re-treatment induced complete radiologic and molecular remission in Hodgkin lymphoma recurring from a previous relapse successfully treated by pembrolizumab

  • Yok-Lam KwongEmail author
  • Florence Loong
  • Pek-Lan Khong
Letter to the Editor

Dear Editor,

The neoplastic Reed-Sternberg (RS) cells in classical Hodgkin lymphoma (cHL) characteristically over-express the programmed cell death ligand 1 (PDL1) and PDL2. Ligation of PDL1 and PDL2 with the inhibitory receptor PD1 on effector T cells is a mechanism by which RS cells escape immunosurveillance. Accordingly, blockade of PDL1/PDL2 binding to PD1 on effector T cells with anti-PD1 antibodies re-establishes anti-lymphoma immunity and is a novel therapeutic strategy for relapsed/refractory cHL [1].

Studies of two anti-PD1 antibodies nivolumab [2] and pembrolizumab [3] in relapsed/refractory cHL showed overall response rates (ORR) of 65–87% and complete response rates (CR) of 16–17%. The optimal post-remission strategies for patients treated with anti-PD1 antibodies have not been defined. Hematopoietic stem cell transplantation (HSCT) is performed for eligible patients. For HSCT-ineligible patients, a continuation of anti-PD1 antibodies is adopted. However, for patients...

Notes

Author contribution

Y.L. Kwong: treated the patient and wrote and approved the manuscript

F. Loong: performed the histopathologic diagnosis and wrote and approved the manuscript

P.L. Khong: performed the radiologic diagnosis and wrote and approved the manuscript

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Not applicable.

Informed consent

Patient gave informed consent to treatment.

References

  1. 1.
    Mottok A, Steidl C (2018) Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood 131(15):1654–1665CrossRefGoogle Scholar
  2. 2.
    Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372(4):311–319CrossRefGoogle Scholar
  3. 3.
    Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH (2016) Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34(31):3733–3739CrossRefGoogle Scholar
  4. 4.
    Kwong YL, Lopes D, Khong PL (2017) Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma. Br J Haematol 176(1):131–132CrossRefGoogle Scholar
  5. 5.
    Chan TS, Luk TH, Lau JS, Khong PL, Kwong YL (2017) Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. Ann Hematol 96(4):647–651CrossRefGoogle Scholar
  6. 6.
    Au WY, Srivastava G, Wong KY, Chung LP, Ma SK, Wan TS, Kwong YL (2004) Transformation of diffuse large B-cell lymphoma into pre-B acute lymphoblastic leukemia: clinicopathologic features and clonal relationship. Hum Pathol 35(7):900–903CrossRefGoogle Scholar
  7. 7.
    Kwong YL, Pang AW, Leung AY, Chim CS, Tse E (2014) Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia 28(4):865–870CrossRefGoogle Scholar
  8. 8.
    Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O’Donnell E, Neuberg D, Shipp MA (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18(6):1611–1618CrossRefGoogle Scholar
  9. 9.
    Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E (2017) PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase. Blood 129(17):2437–2442CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medicine, Professorial BlockQueen Mary HospitalHong KongChina
  2. 2.Department of PathologyQueen Mary HospitalHong KongChina
  3. 3.Department of Diagnostic RadiologyQueen Mary HospitalHong KongChina

Personalised recommendations